HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

496.758

-15.630-3.05%

Number of Gainers:6

Number of Losers:25

Number of Flat:2

PE:- -

High:512.373

Open:512.373

Low:495.812

Close:512.388

Volume:95.41M

Turnover:2.18B

Market Cap:315.16B

Float Cap:281.17B

Loading ...

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?

Simply Wall St.

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS

We Might See A Profit From Venus Medtech (Hangzhou) Inc. (HKG:2500) Soon

Simply Wall St.

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS

HBM Holdings Clarifies Reasons Behind Executive Director's Departure

Alphamab Oncology Files HKEX Next-Day Disclosure Return for Share Buyback at HKD 8.57

CanSino Biologics' Global Revenue Soars 4,724% in First Half, Systemic Expansion Strategy Unlocks Growth Potential

Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira

KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions

THOMSON REUTERS

KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection

THOMSON REUTERS

OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment

Ocumension Completes Enrollment in China Phase III Trial of Dry Eye Drug OT-211

REMEGEN Discloses Cumulative Buyback of 41,000 A-Shares by End of August

Executive Director Wang Yuxiao Reduces Stake in Remegen (09995) by 13,500 Shares at Approximately HK$81.54 Each

Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects

GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd

HBM Holdings Says Dr. Yiping Rong Resigns as Executive Director to Focus on Other Commitments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/BK1574/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":496.75812,"timestamp":1789027721934,"preClose":512.3882,"halted":0,"volume":95412163,"delay":0,"changeRate":-0.030504,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-15.630066,"latestTime":"09-10 16:00:00","open":512.3731,"high":512.3731,"low":495.81204,"amount":2180840440,"amplitude":0.032321,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"pbRate":3.809281,"peRate":169.439728,"turnoverRate":0.003564,"increases":5,"decrements":26,"flats":1,"marketCap":315159581920,"floatMarketCap":281174468760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":512.3731,"amplitude":0.032321,"preClose":512.3882,"low":495.81204,"pbRate":"3.809281","latestPrice":496.75812,"volume":95412163,"delay":0,"open":512.3731,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":515.473,"twentyDayClose":536.134,"sixtyDayClose":437.19,"secType":"PLATE","market":"HK","turnoverRate":0.003564,"peRate":169.439728,"marketCap":315159581920,"floatMarketCap":281174468760,"timestamp":1789027721934,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664582856","title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664582856","media":"MT Newswires","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664582856?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:42","pubTimestamp":1788399758,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1587","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828727","title":"Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828727","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828727?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:38","pubTimestamp":1788395893,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) stock is in focus after the company released its 2026 interim update, highlighting fresh CS2009 clinical data, stronger pralsetinib uptake, and progress toward global Phase III trials.\nAt a latest share price of HK$6.18, CStone Pharmaceuticals has seen a 1 month share price return of 42.07% and a 90 day share price return of 23.35%. However, the 1 year total shareholder return declined 48.93%, which hints that recent clinical and interim results have...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/is-cstone-pharmaceuticals-sehk2616-fully-valued-on-interim-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/is-cstone-pharmaceuticals-sehk2616-fully-valued-on-interim-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","LU2065732104.USD","DCF","BK4097","PRGS","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664440588","title":"Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664440588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664440588?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:02","pubTimestamp":1788390131,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U147:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348767384.USD","LU0348827113.USD","LU0348783233.USD","LU0540923850.HKD","LU1720050803.USD","LU0348766576.USD","09926","IE00BPRC5H50.USD","LU0348735423.USD","LU2476274308.USD","LU0634319403.HKD","LU1794554557.SGD","LU0561508036.HKD","KURE","IE00B543WZ88.USD","LU1961090484.USD","BK1574","LU0417516902.SGD","LU2488822045.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0348825331.USD","LU2399975544.HKD","BK1161","LU2778985437.USD","LU0417516571.SGD","LU0417516738.SGD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828744","title":"We Might See A Profit From Venus Medtech (Hangzhou) Inc. (HKG:2500) Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828744?lang=en_us&edition=fundamental","pubTime":"2026-09-03 06:19","pubTimestamp":1788387559,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Venus Medtech (Hangzhou) Inc.'s ( HKG:2500 ) business as it appears the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-2500/venus-medtech-hangzhou-shares/news/we-might-see-a-profit-from-venus-medtech-hangzhou-inc-hkg250","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-2500/venus-medtech-hangzhou-shares/news/we-might-see-a-profit-from-venus-medtech-hangzhou-inc-hkg250","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02500","BK1574","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841457","title":"Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841457","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841457?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:01","pubTimestamp":1788382889,"startTime":"0","endTime":"0","summary":"Akeso says ivonescimab meets overall survival endpoint in Phase III HARMONi-2 lung cancer trialAkeso reported its Phase III HARMONi-2 trial met a key overall survival endpoint in an interim analysis v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL9yKX9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0540923850.HKD","LU0348767384.USD","LU1961090484.USD","IE00B543WZ88.USD","LU0348784397.USD","LU2476274720.SGD","BK1161","LU0417516738.SGD","LU2778985437.USD","LU0417516571.SGD","LU2476274308.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU2399975544.HKD","LU0348825331.USD","LU0417516902.SGD","09926","IE00BPRC5H50.USD","LU0348766576.USD","LU0634319403.HKD","LU2488822045.USD","LU0561508036.HKD","LU1720050803.USD","BK1574","LU0348827113.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664684112","title":"Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2664684112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664684112?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348784397.USD","LU2476274720.SGD","LU0348825331.USD","IE00B5MMRT66.SGD","LU0348827113.USD","LU1720050803.USD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","LU0540923850.HKD","LU0348735423.USD","LU2778985437.USD","LU0417516571.SGD","LU0417516902.SGD","BK1574","LU2399975544.HKD","09926","LU1961090484.USD","LU1794554557.SGD","LU0348767384.USD","LU0417516738.SGD","LU2476274308.USD","IE00BPRC5H50.USD","KURE","LU2488822045.USD","LU0561508036.HKD","LU0348766576.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664125841","title":"Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2664125841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664125841?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382834,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U140:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1961090484.USD","IE00BPRC5H50.USD","BK1161","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD","LU2476274308.USD","BK1574","LU1720050803.USD","LU0348767384.USD","LU2488822045.USD","LU0561508036.HKD","LU0348827113.USD","LU0348735423.USD","09926","LU0540923850.HKD","LU0348784397.USD","LU1794554557.SGD","LU0417516738.SGD","KURE","LU0348825331.USD","LU2399975544.HKD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181297414","title":"HBM Holdings Clarifies Reasons Behind Executive Director's Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=1181297414","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181297414?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:41","pubTimestamp":1788360072,"startTime":"0","endTime":"0","summary":"On September 2nd, HBM Holdings-B issued a supplementary announcement to provide further details on the changes to its directors and authorized representatives that were disclosed on August 27th. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817416","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return for Share Buyback at HKD 8.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817416","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664817416?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:27","pubTimestamp":1788359260,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return for share buyback at HKD 8.57Alphamab Oncology repurchased 115,000 shares on Sept. 2, holding them as treasury shares; no shares were cancelled.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL3rSzX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198828841","title":"CanSino Biologics' Global Revenue Soars 4,724% in First Half, Systemic Expansion Strategy Unlocks Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1198828841","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198828841?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:10","pubTimestamp":1788354651,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. has released its interim report for the first half of 2026, revealing total revenue of RMB 550 million, a 43.81% increase year-on-year, alongside a significant narrowing of its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","BK1515","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664478814","title":"Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=2664478814","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664478814?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354268,"startTime":"0","endTime":"0","summary":"Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to AeiraKeymed entered an exclusive licensing deal with Aeira to register and commercialize Sta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7LCJLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814417","title":"KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814417?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1574","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144128","title":"KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1587","BK1583","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126045427","title":"OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1126045427","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126045427?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:16","pubTimestamp":1788351373,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced the completion of patient enrollment for its Phase III clinical trial of OT-211 (TRYPTYR® acotiamide eye drops) in the People's Republic of China, with a total of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBJ","PSYK","BK1191","IBBQ","BK1574","01477","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811874","title":"Ocumension Completes Enrollment in China Phase III Trial of Dry Eye Drug OT-211","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811874","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811874?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:13","pubTimestamp":1788351237,"startTime":"0","endTime":"0","summary":"Ocumension completes enrollment in China Phase III trial of dry eye drug OT-211Ocumension Therapeutics completed patient enrollment in a Phase III China trial of OT-211 for dry eye disease.Results hav","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLbTKXg6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118027728","title":"REMEGEN Discloses Cumulative Buyback of 41,000 A-Shares by End of August","url":"https://stock-news.laohu8.com/highlight/detail?id=1118027728","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118027728?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:04","pubTimestamp":1788350652,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) has released an announcement detailing its share repurchase activities.As of August 31, 2026, the company had repurchased a cumulative total of 41,000 A-shares through the Shanghai...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","399300","LU2148510915.USD","83188","LU1969619763.USD","BK1161","83130","07233","159982","02827","LU2328871848.SGD","03130","688331","LU1064131003.USD","82846","03188","02846","BK1583","09995","LU2488822045.USD","BK1147","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164591890","title":"Executive Director Wang Yuxiao Reduces Stake in Remegen (09995) by 13,500 Shares at Approximately HK$81.54 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1164591890","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164591890?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:46","pubTimestamp":1788349577,"startTime":"0","endTime":"0","summary":"According to the latest disclosures from the Hong Kong Stock Exchange, on August 27, executive director Wang Yuxiao sold 13,500 shares of Remegen (09995) at an average price of HK$81.5352 per share,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1969619763.USD","09995","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","BK0239","BK1574","EWH","LU2488822045.USD","LU1064131003.USD","BK1161","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149967319","title":"Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=1149967319","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149967319?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:44","pubTimestamp":1788349448,"startTime":"0","endTime":"0","summary":"To advance high-quality development in the medical device industry and uncover promising local innovations, the Shenzhen Municipal Market Supervision Administration recently organized a roadshow and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","159883","LNGR","BK1583","RSPH","IEIH","BK1574","HART","MEDX","GDOC","MDEV","PTH","BK1100","LGHT","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186482960","title":"GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd","url":"https://stock-news.laohu8.com/highlight/detail?id=1186482960","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186482960?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:08","pubTimestamp":1788347291,"startTime":"0","endTime":"0","summary":"On September 2nd, GENFLEET-B (02595) announced a share repurchase, investing approximately HK$1.0763 million to buy back 39,000 shares.The buyback was conducted at a total cost of HK$1.0763 million, reflecting the company's capital management strategy and its view on the current market valuation.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","BK1574","BK1515","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664892082","title":"HBM Holdings Says Dr. Yiping Rong Resigns as Executive Director to Focus on Other Commitments","url":"https://stock-news.laohu8.com/highlight/detail?id=2664892082","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664892082?lang=en_us&edition=fundamental","pubTime":"2026-09-02 16:33","pubTimestamp":1788338000,"startTime":"0","endTime":"0","summary":"HBM Holdings says Dr. Yiping Rong resigns as executive director to focus on other commitmentsHBM issued a supplemental clarification on the Aug. 27 management changes.Executive director Yiping Rong resigned to reallocate time to other business commitments.All other details in the Aug. 27 announcement remain unchanged, with the changes effective Aug. 27.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on September 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8nk3b1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":7,"totalSize":255,"code":"91000000","status":"200"}]}}